Alpha Stem Cell Clinics Trials

The Alpha Stem Cell Clinics Network is pursuing its goal to accelerate the development and delivery of stem cell treatments to patients through high quality clinical trials. 

Browse the list of ongoing trials at Alpha Stem Cell Clinic locations in the table below. You can sort trials based on different fields by clicking on the appropriate column header. Trials are automatically listed by status of trial enrollment and Alpha Clinic location.

Alpha Clinic Trials

Alpha Clinic	Alpha Clinic Contact	Trial Sponsor	Disease Indication	Clinical Trial Name	Status of Enrollment	Learn More
City of Hope	Cara Nolan 626-256-4673 ext 32341 cnolan@coh.org	Juno Therapeutics	Cancer - Leukemia	Long-Term Follow-up Study for Patients Previously Treated With JCAR015	No longer active
UCSD	(844) 317-7836 alphastemcellclinic@ucsd.edu	UCSD	Cancer - Leukemia	Extension Study of UC-961 (Cirmtuzumab) for Patients With Chronic Lymphocytic Leukemia Treated Previously With UC-961	No longer active
UCSD & City of Hope	(844) 317-7836 alphastemcellclinic@ucsd.edu	UCSD	Cancer - Leukemia	A Study of the Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies	Active, not recruiting
City of Hope	Rie Miyahira 626-256-4673 ext 80032 rmiyahira@coh.org	Angiocrine Bioscience	Cancer - Leukemia	A Phase 1B, Open Label, Multi-Center Trial of AB-110 in Adults With Hematologic Malignancies Undergoing Cord Blood Transplantation	Recruiting
UCSF	Julie DeCaris 510-428-3885 ext 2739 jdecaris@mail.cho.org	Seattle Children’s Hospital Foundation	Cancer - Leukemia	A Pediatric and Young Adult Trial of Genetically Modified T Cells Directed Against CD19 for Relapsed/Refractory CD19+ Leukemia	No longer active	NCT02028455
UCSD	Barbara Parker, MD 858-822-6135 baparker@ucsd.edu Rebecca Shatsky, MD 858-657-7000 rshatsky@ucsd.edu	UCSD	Cancer - Breast	Study of Cirmtuzumab and Paclitaxel for Metastatic or Locally Advanced, Unresectable Breast Cancer	Active, not recruiting
City of Hope	Jana Portnow, MD (626) 256-4673 ext 62909 jportnow@coh.org	City of Hope	Cancer - Brain	Genetically Modified Neural Stem Cells, Flucytosine, and Leucovorin for Treating Patients With Recurrent High-Grade Gliomas	Active, not recruiting
City of Hope	Jana Portnow, MD (626) 256-4673 ext 62909 jportnow@coh.org	City of Hope	Cancer - Brain	Carboxylesterase-Expressing Allogeneic Neural Stem Cells and Irinotecan Hydrochloride in Treating Patients With Recurrent High-Grade Gliomas	Recruiting
City of Hope	Behnam Badie, MD (626) 256-4673 ext 60098 bbadie@coh.org	City of Hope	Cancer - Brain	Genetically Modified T-cells in Treating Patients With Recurrent or Refractory Malignant Glioma	Recruiting
UCI	UCI Stem Cell Clinic (949) 824-3990 stemcell@uci.edu	ImmunoCellular Therapeutics	Cancer - Brain	A Phase 3 Randomized Double-blind, Controlled Study of ICT-107 With Maintenance Temozolomide (TMZ) in Newly Diagnosed Glioblastoma	No longer active
UCI & UCSD & UC Davis	UCI Stem Cell Clinic 949-824-3990 stemcell@uci.edu Jane McCluskey 916-703-9302 jmccluskey@ucdavis.edu	Aivita Biomedical	Cancer - Brain	Autologous Dendritic Cells Loaded With Autologous Tumor Associated Antigens for Treatment of Newly Diagnosed Glioblastoma	Active, not recruiting
City of Hope	Behnam Badie, MD; 626-256-4673 bbadie@coh.org	City of Hope	Cancer - Brain	Memory-Enriched T Cells in Treating Patients With Recurrent or Refractory Grade III-IV Glioma	Recruiting
City of Hope	Fatemeh Bidmeshki 626-218-9393 fbidmeshki@coh.org	City of Hope	Cancer - Brain	HER2-CAR T Cells in Treating Participants With Brain or Leptomeningeal Metastases	Recruiting
UCSD	UCSD Stem Cell Clinic (844) 317-7836 alphastemcellclinic@ucsd.edu	Persimmune, Inc.	Cancer - Blood	Collection of Bone Marrow, Peripheral Blood (PB), Epithelial Tissue, and Saliva Samples From Patients With Myelodysplastic Syndromes (MDS) to Identify MDS-Specific Antigens	No longer active
UCSD	(844) 317-7836 alphastemcellclinic@ucsd.edu	Persimmune, Inc.	Cancer - Blood	Personalized Adoptive Cellular Therapy Targeting MDS Stem Cell Neoantigens (PACTN)	No longer active
UCLA	Sarah Larson, MD 310-206-8477 slarson@mednet.ucla.edu	UCLA	Cancer	TCR Genetically Engineered PBMC and PBSC After Melphalan Conditioning Regimen in Treating Participants With Relapsed and Refractory Multiple Myeloma (NYSCT MM)	No longer active
UCI	UCI Stem Cell Clinic (949) 824-3990 stemcell@uci.edu	Stratetech	Burn wounds	StrataGraft® Skin Tissue in the Promotion of Autologous Skin Regeneration of Complex Skin Defects Due to Thermal Burns That Contain Intact Dermal Elements	No longer active
UCLA & UCI	UCLA: Courtney Real, BSN 310-267-7433 creal@mednet.ucla.edu UCI: UCI Stem Cell Clinic (949) 824-3990 stemcell@uci.edu	SanBio	Brain Injury	A Double-Blind, Controlled Phase 2 Study of the Safety and Efficacy of Modified Stem Cells (SB623) in Patients With Chronic Motor Deficit From Traumatic Brain Injury (TBI)	No longer active
UCSF & UCLA	Marci Moriarty, BSN, RN 510-428-3885 ext 5396 mmoriarty@mail.cho.org Bruck Habtemariam 310-794-0242 bhabtemariam@mednet.ucla.edu	Sangamo Therapeutics	Blood Disorder - Beta-Thalassemia	A Study to Assess the Safety, Tolerability, and Efficacy of ST-400 for Treatment of Transfusion-Dependent Beta-thalassemia (TDT)	No longer active	NCT03432364
UCSF	Romobia Hutchinson 415-476-9326 romobia.hutchinson@ucsf.edu	UCSF	Blood Disorder - Alpha Thalassemia Major	In Utero Hematopoietic Stem Cell Transplantation for Alpha-thalassemia Major (ATM)	Recruiting
UCSF	Gabrielle Garcia Gabriel.Garcia@ucsf.edu	Allo Vir, Inc.	BK Viremia in Kidney Transplant Recipients	Phase 2 study in patients with BK Viremia in Kidney Transplant Recipients	No longer active	NCT04605484
UC Davis	Jane McCluskey 916-703-9302 jmccluskey@ucdavis.edu	UC Davis	B-Cell Leukemia	A Phase 1b-2 Study of the ROR1-Targeting Monoclonal Antibody, Cirmtuzumab, and the Bruton Tyrosine Kinase Inhibitor, Ibrutinib, in Patients with B-Cell Lymphoid Malignancies	Active, not recruiting
UCSF	Allegra Koch 415-476-2381 Allegra.koch@ucsf.edu	CRISPR Therapeutics	B Cell Malignancies Non-hodgkin Lymphoma, B-cell Lymphoma, Adult B Cell ALL	A Phase 1 Dose Escalation and Cohort Expansion Study of the Safety and Efficacy of Anti-CD19 Allogeneic CRISPR-Cas9–Engineered T Cells (CTX110) in Subjects With Relapsed or Refractory B Cell Malignancies	No longer active	NCT04035434
UCSF & UCSD & CIRM	Jane McCluskey 916-703-9302 jmccluskey@ucdavis.edu	CIRM	ARDS/COVID	Prospective, Randomized, Multi-center Phase 2 Clinical Trial of Allogeneic Bone Marrow-derived Human Mesenchymal Stromal Cells (hMSCs) for the Treatment of Acute Respiratory Distress Syndrome (ARDS)	No longer active	Prospective, Randomized, Multi-center Phase 2 Clinical Trial of Allogeneic Bone Marrow-derived Human Mesenchymal Stromal Cells (
UCI	UCI Stem Cell Clinic (949) 824-3990 stemcell@uci.edu	BrainStorm Cell Therapeutics	Amyotrophic Lateral Sclerosis (ALS)	A phase 3, randomized, double-blind, placebo-controlled multicenter study to evaluate efficacy and safety of repeated administrations of NurOwn® (autologous mesenchymal stem cells secreting neurotrophic factors) in participants with ALS	No longer active
UCI	UCI Stem Cell Clinic (949) 824-3990 stemcell@uci.edu	Longeveron	Aging frailty	Phase IIb Trial to Evaluate Longeveron Mesenchymal Stem Cells to Treat Aging Frailty	Active, not recruiting
UC Davis	Jane McCluskey 916-703-9302 jmccluskey@ucdavis.edu	Kite Pharma	Advanced Cancer	A Study Evaluating the Safety and Efficacy of MAGE-A3/A6 T Cell Receptor Engineered T Cells (KITE-718) in HLA-DPB1*04:01 Positive Subjects with Advanced Cancers	No longer active
UCSF	Hanjing Zhou 415-502-7434 hanging.zhou@ucsf.edu	Department of Defense	Acute Respiratory Distress Syndrome (ARDS)	A Phase 2b, Randomized, Double-blind, Placebo-controlled, Multicenter Clinical Trial of Allogenic Bone Marrow-derived Human Mesenchymal Stromal Cells for the Treatment of Acute Respiratory Distress Syndrome After Trauma	No longer active
UC Davis	Jane McCluskey 916-703-9302 jmccluskey@ucdavis.edu	Autolus	Acute Lymphoblastic Leukaemia	An Open-Label, Multi-Centre, Phase Ib/II Study Evaluating the Safety and Efficacy of AUTO1, a CAR T Cell Treatment Targeting CD19, in Adult Patients with Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia	Active, not recruiting	An Open-Label, Multi-Centre, Phase Ib/II Study Evaluating the Safety and Efficacy of AUTO1, a CAR T Cell Treatment Targeting CD1

Clinical trials conducted at CIRM Alpha Stem Cell Clinics must comply with applicable federal and state laws and medical and ethical standards governing the conduct of human clinical trials. If you or a family member is interested in participating in a clinical trial, please visit clinicaltrials.gov to find a trial near you.

Find Out More:
About Alpha Stem Cell Clinics
Alpha Clinics News